Skip to main
KRYS
KRYS logo

Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech (KRYS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 80%
Buy 13%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Krystal Biotech Inc. reported a significant revenue increase for its product Vyjuvek, achieving $91.1 million in net revenue for the third quarter of FY24, representing a 9% rise from the previous quarter, with full-year revenues reaching $290.5 million in line with projections. The company is also showing promising preclinical results for its gene therapies and anticipates a pickup in approval rates for additional products beginning in 2025, further supporting its growth potential. With strong patient compliance and discussions around implementing a share repurchase program, Krystal Biotech appears well-positioned for profitability and may even explore dividend opportunities in the future.

Bears say

Krystal Biotech Inc. faces a negative outlook due to several fundamental challenges, including a downward trend in new reimbursement approvals, with projections indicating a decline from 70 new adds in 2Q24 to just 50 in 4Q24. Additionally, the competitive landscape in the gene therapy sector remains precarious, as the company could encounter significant recruitment difficulties for clinical trials due to the rarity of the diseases it targets, compounded by the complexities of manufacturing novel gene therapy products. Moreover, potential setbacks in clinical trials, unforeseen safety issues, and the necessity for adequate funding to advance its drug development may further impede the company’s financial stability and growth prospects.

Krystal Biotech (KRYS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 13% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Krystal Biotech (KRYS) Forecast

Analysts have given Krystal Biotech (KRYS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, Krystal Biotech (KRYS) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $174.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $174.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Krystal Biotech (KRYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.